InvestorsHub Logo
Followers 834
Posts 120246
Boards Moderated 18
Alias Born 09/05/2002

Re: tinkershaw post# 1448

Thursday, 02/03/2011 5:21:07 AM

Thursday, February 03, 2011 5:21:07 AM

Post# of 20689
It makes no difference whether MYL’s Copaxone is a serious contender; regardless, the FTC would view a Teva acquisition of MNTA as reducing competition in the US Copaxone market and would nix such a deal.

I’m as certain of the above as I’ve been of anything I’ve ever posted on iHub.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”